Evidence map›Paper›PMID 42415779›Full record

ReviewFrontiers in medicine2026

Pathogenic mechanisms in Fabry disease.

Siming Wang, Chengyue Sun

Abstract readReview
In one paragraph

Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Siming WangDepartment of Neurology, Peking University People's Hospital, Beijing, China.
Chengyue SunDepartment of Neurology, Peking University People's Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anderson-Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme α-galactosidase A, resulting in progressive accumulation of glycosphingolipids, particularly globotriaosylceramide (Gb3), across multiple organs. FD exhibits marked phenotypic variability influenced by residual enzyme activity, mutation type, and X-chromosome inactivation. Pathogenic mechanisms involve genetic, enzymatic, and metabolic dysregulation, leading to lysosomal dysfunction, inflammation, oxidative stress, mitochondrial impairment, and autophagic defects. Multi-system involvement includes vasculopathy, cardiovascular abnormalities such as left ventricular hypertrophy and arrhythmias, progressive renal injury, central nervous system lesions with cognitive and psychiatric manifestations, and peripheral neuropathy characterized by pain and autonomic dysfunction. Accumulation of Gb3 and its derivative globotriaosylsphingosine (lyso-Gb3) underlies both direct cellular toxicity and secondary pathological processes, including inflammatory activation, oxidative damage, and ion-channel dysregulation. This review synthesizes current understanding of the molecular and cellular pathogenesis of FD, highlights mechanisms underlying phenotypic variability, and integrates organ-specific manifestations.

Indexed as

Fabry diseaseGb3 accumulationlysosomal storage disordermulti-system involvementα-galactosidase A

Identifiers

PMID42415779
PMCPMC13337472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.